Debt Financing

Biomerica (BMRA) sells Diagnosis stake for $500,000 secured note

BMRA

Biomerica (Nasdaq: BMRA) agreed on May 29, 2026 to sell its 6% stake in Diagnosis S.A. to buyers affiliated with its chief executive, in return for a $500,000 secured note the company issued at 8%.

Investor Chat

Scorecard

BMRADebt
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-08
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record
Investment Attractiveness: 4.7/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

Debt: $500,000 secured promissory note

After (pro forma)N/AOwnership dilutionN/A

By the aibio.space news desk

A judge's gavel on a courtroom bench
A judge's gavel on a courtroom bench. Photo: Joe Gratz, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.

Biomerica, Inc. (Nasdaq: BMRA) agreed on May 29, 2026 to sell 78,750 shares of Diagnosis S.A. to buyers affiliated with Zackary Irani, its chief executive. The shares are about 6% of the Poland-based medical products maker. The buyers paid the $500,000 purchase price, and the company issued them a secured promissory term note in return. The note bears 8% interest and matures 12 months after the effective date. The company reported the agreement in a Form 8-K filed June 4, 2026.

Why is this important: Biomerica had cash and cash equivalents of approximately $1,336,000 at February 28, 2026. The company owes $500,000 on a note secured by a lien on the Diagnosis shares. The agreement says that, on completion of the share transfer, principal and interest above 60 days of interest will be forgiven in full. Otherwise the note is due 12 months after the effective date.

Zackary S. Irani is the chief executive officer and signed the 8-K. Gary Lu, the chief financial officer until April 14, 2026, resigned effective on that date, according to the Form 10-Q filed April 13, 2026. In our view, a note from buyers tied to the chief executive, arranged while the company reports recurring losses, is a related-party arrangement the board should explain on the record. The quarterly report shows working capital of approximately $2,562,000 and an accumulated deficit of approximately $55,798,000, and it carries going-concern language. It says management assesses whether the company can fund its costs for the next twelve months to decide whether substantial doubt exists about its ability to continue as a going concern.

The Diagnosis stake and the note terms

The purchase agreement is dated May 29, 2026 and names the buyers in its Exhibit A. The note was issued to a lead buyer. The closing is set for the date of the agreement or another date the parties agree, and the agreement expects the Polish regulatory approvals for the transfer to be satisfied within thirty days after the effective date. At the closing, the company must have the transfer reflected in the shareholder register of Diagnosis S.A. The shares are 78,750 common shares, about 6% of Diagnosis S.A., a medical products producer and distributor. The note's lien covers all of the company's right, title and interest in the shares. The agreement describes the note as forgivable upon the transfer of the shares, as set out above.

The 8-K names no underwriter, placement agent or outside lender for the transaction.

The inFoods IBS platform and the cash position

The company's primary focus is patented diagnostic-guided therapy (DGT) products for gastrointestinal disease, such as irritable bowel syndrome. Its inFoods IBS product, developed on the inFoods technology platform, uses a simple blood sample to identify foods that may cause an abnormally high immune response in a patient with IBS. The company says removing those foods from the diet may alleviate symptoms such as abdominal pain, cramping, bloating, diarrhea and constipation. The product has been introduced to select gastroenterology physician groups in multiple states and regions. The 10-Q says the company's other existing products are primarily focused on gastrointestinal diseases, food intolerances and certain esoteric tests.

The 10-Q refers to clinical studies and to lower clinical trial expenses, but it reports no clinical outcome data for inFoods IBS. As of February 28, 2026, the company had 3,029,444 common shares outstanding. Its fiscal year ends May 31, and the note's 12-month term runs from May 29, 2026.

The note is not the company's only source of new money this year. The 10-Q says that in the nine months ended February 28, 2026, the company sold 414,633 shares under its 2024 ATM Offering, a program of up to $5,500,000, at prices from $2.42 to $4.02 a share. Those sales brought in approximately $1,495,000 in gross proceeds and $1,455,000 in net proceeds. In our view, the company is raising money from insiders and from the market at the same time, and the filings do not show how it weighs the two.

The next dated item in the filing is the note's maturity, 12 months after the May 29, 2026 effective date, unless the note is forgiven on transfer of the shares, as the agreement describes.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.